Jennifer Jao1, Elaine J Abrams. 1. From the *Department of Medicine, Divisions of Infectious Diseases and General Medicine, Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine, Mount Sinai; and †ICAP, Mailman School of Public Health and College of Physicians and Surgeons, Columbia University, New York, NY.
Abstract
BACKGROUND: Despite a wide body of literature supporting the use of antenatal antiretrovirals (ARV) for the prevention of mother-to-child transmission, there remains a need for continued monitoring as the intrauterine interval is a critical period during which fetal programming influences the future health and development of the child. METHODS: We conducted a systematic review of the current literature addressing potential metabolic complications of in utero HIV and ARV exposure. We describe studies evaluating metabolic outcomes such as intrauterine and early postnatal growth, bone health and mitochondrial toxicity. RESULTS: Overall, infants exposed to HIV/ARV do not appear to exhibit vastly compromised intrauterine or early postnatal growth. However, some studies on the effect of combination antiretroviral therapy on small for gestational age and low birth weight outcomes in low-middle income countries show a risk for small for gestational age/low birth weight while those in the United States do not. Postnatal growth to 1 year does not appear to be affected by intrauterine tenofovir exposure in African studies, but a US study found statistically significant differences in length for age z scores (LAZ) at 1 year. Little data exists on long-term bone health. Mitochondrial toxicity including abnormal mitochondrial morphology and DNA content, as well as neurologic deficits and death, have been demonstrated in HIV/ARV-exposed infants. CONCLUSION: Although gross measures of metabolic well-being appear to be reassuring, careful vigilance of even small risks for potential serious adverse effects to infants exposed to intrauterine HIV/ARVs is warranted as intrauterine fetal metabolic programming may substantially impact the future health of the child.
BACKGROUND: Despite a wide body of literature supporting the use of antenatal antiretrovirals (ARV) for the prevention of mother-to-child transmission, there remains a need for continued monitoring as the intrauterine interval is a critical period during which fetal programming influences the future health and development of the child. METHODS: We conducted a systematic review of the current literature addressing potential metabolic complications of in utero HIV and ARV exposure. We describe studies evaluating metabolic outcomes such as intrauterine and early postnatal growth, bone health and mitochondrialtoxicity. RESULTS: Overall, infants exposed to HIV/ARV do not appear to exhibit vastly compromised intrauterine or early postnatal growth. However, some studies on the effect of combination antiretroviral therapy on small for gestational age and low birth weight outcomes in low-middle income countries show a risk for small for gestational age/low birth weight while those in the United States do not. Postnatal growth to 1 year does not appear to be affected by intrauterine tenofovir exposure in African studies, but a US study found statistically significant differences in length for age z scores (LAZ) at 1 year. Little data exists on long-term bone health. Mitochondrialtoxicity including abnormal mitochondrial morphology and DNA content, as well as neurologic deficits and death, have been demonstrated in HIV/ARV-exposed infants. CONCLUSION: Although gross measures of metabolic well-being appear to be reassuring, careful vigilance of even small risks for potential serious adverse effects to infants exposed to intrauterine HIV/ARVs is warranted as intrauterine fetal metabolic programming may substantially impact the future health of the child.
Authors: Marilyn J Crain; Paige L Williams; Ray Griner; Katherine Tassiopoulos; Jennifer S Read; Lynne M Mofenson; Kenneth C Rich Journal: Pediatr Infect Dis J Date: 2011-12 Impact factor: 2.129
Authors: A C Ross; T Leong; A Avery; M Castillo-Duran; H Bonilla; D Lebrecht; U A Walker; N Storer; D Labbato; A Khaitan; I Tomanova-Soltys; G A McComsey Journal: HIV Med Date: 2011-11-21 Impact factor: 3.180
Authors: D A Schwartz; S Sungkarat; N Shaffer; J Laosakkitiboran; W Supapol; P Charoenpanich; T Chuangsuwanich; T D Mastro Journal: J Infect Dis Date: 2000-11-08 Impact factor: 5.226
Authors: Jennifer Y Chen; Heather J Ribaudo; Sajini Souda; Natasha Parekh; Anthony Ogwu; Shahin Lockman; Kathleen Powis; Scott Dryden-Peterson; Tracy Creek; William Jimbo; Tebogo Madidimalo; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Infect Dis Date: 2012-10-12 Impact factor: 5.226
Authors: T E Taha; G A Dallabetta; J K Canner; J D Chiphangwi; G Liomba; D R Hoover; P G Miotti Journal: Int J Epidemiol Date: 1995-10 Impact factor: 7.196
Authors: Salina M Torres; Dale M Walker; Consuelo L McCash; Meghan M Carter; Jessica Ming; Edmund M Cordova; Rachel M Pons; Dennis L Cook; Steven K Seilkop; William C Copeland; Vernon E Walker Journal: Environ Mol Mutagen Date: 2009-01 Impact factor: 3.216
Authors: Carmen J Marsit; Sean S Brummel; Deborah Kacanek; George R Seage; Stephen A Spector; David A Armstrong; Barry M Lester; Kenneth Rich Journal: Epigenetics Date: 2015 Impact factor: 4.528
Authors: Keith M Godfrey; Rebecca M Reynolds; Susan L Prescott; Moffat Nyirenda; Vincent W V Jaddoe; Johan G Eriksson; Birit F P Broekman Journal: Lancet Diabetes Endocrinol Date: 2016-10-12 Impact factor: 32.069
Authors: Jennifer Jao; Denise L Jacobson; Wendy Yu; William Borkowsky; Mitchell E Geffner; Elizabeth J McFarland; Kunjal Patel; Paige L Williams; Tracie Miller Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: Charlotte Lane; Emily A Bobrow; Dieudonne Ndatimana; Gilles F Ndayisaba; Linda S Adair Journal: Am J Hum Biol Date: 2019-08-09 Impact factor: 1.937
Authors: Malango T Msukwa; Janne Estill; Andreas D Haas; Joep J van Oosterhout; Lyson Tenthani; Mary-Ann Davies; Kali Tal; Nozgechi Phiri; Adrian Spoerri; Bryan C Mthiko; Frank Chimbwandira; Olivia Keiser Journal: AIDS Date: 2018-09-24 Impact factor: 4.177
Authors: Charlotte E Lane; Elizabeth M Widen; Shalean M Collins; Sera L Young Journal: J Acquir Immune Defic Syndr Date: 2020-10-01 Impact factor: 3.771